Merck, NanoBio team on preclinical RSV deal

Ann Arbor, MI-based NanoBio Corporation said it's teaming up with an unnamed Merck subsidiary on preclinical development of an intranasal vaccine for Respiratory Syncytial Virus (RSV). Researchers will be studying a combination of Merck's RSV antigen with NanoBio's NanoStat adjuvant technology. "RSV remains a major cause of serious lung infections in children and the elderly," said NanoBio founder and CEO James Baker, Jr. in a statement. "We look forward to working together in an effort to advance RSV vaccine research." NanoBio release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.